Skip to main content
Log in

Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”

  • Letter to the Editor
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Yu C. Comment on: “Outcomes for metastatic colorectal cancer based on microsatellite instability: results from the South Australian Metastatic Colorectal Cancer Registry”. Target Oncol. 2019. http://doi.org/10.1007/s11523-019-00639-3.

  2. Chong LC, Townsend AR, Young J, et al. Outcomes for metastatic colorectal cancer based on microsatellite instability: results from the South Australian Metastatic Colorectal Cancer Registry. Target Oncol. 2019;14(1):85–91.

    Article  PubMed  Google Scholar 

  3. Goldstein J, Tran B, Ensor J, et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014;25(5):1032–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bartley AN, Luthra R, Saraiya DS, et al. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing. Cancer Prev Res. 2012;5:320–7.

    Article  Google Scholar 

  5. Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–9.

    Article  CAS  PubMed  Google Scholar 

  6. Study of pembrolizumab (MK-3475) vs standard therapy in participants with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) stage IV colorectal carcinoma (MK-3475-177/KEYNOTE-177). ClinicalTrials.gov Identifier: NCT02563002. https://www.clinicaltrials.gov. Accessed 21 Apr 2019.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Timothy J. Price.

Ethics declarations

Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Li Chia Chong, Christos Karapetis, Amitesh Roy, Robert Padbury, and Timothy J. Price have no conflicts of interest that are directly relevant to the contents of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chong, L.C., Karapetis, C., Roy, A. et al. Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”. Targ Oncol 14, 367–368 (2019). https://doi.org/10.1007/s11523-019-00640-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-019-00640-w

Navigation